- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
別名: SRT501 中文名稱:白藜蘆醇
Resveratrol具有廣泛靶點,包括環(huán)氧酶(如COX, IC50=1.1 μM)、脂肪氧合酶(LOC, IC50=2.7 μM)、sirtuins和其他蛋白質(zhì)。它是一種天然的植物抗毒素,具有抗癌,抗炎,降血糖和其他有益心血管的作用。Resveratrol可誘導線粒體自噬、細胞自噬和自噬依賴性的凋亡。
Resveratrol Chemical Structure
CAS: 501-36-0
相關(guān)產(chǎn)品 | Spautin-1 PIK-III DC661 Lys05 Autophinib SMER28 EAD1 Flubendazole EN6 ROC-325 NSC 185058 MPP+ iodide IITZ-01 STF-62247 QX77 CA-5f Lucanthone CA77.1 Daurisoline | 點擊展開 |
---|---|---|
相關(guān)化合物庫 | 激酶抑制劑庫 FDA藥物庫 天然產(chǎn)物庫 已知活性藥物庫-I 生物活性庫Ⅱ | 點擊展開 |
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
Hepa 1c1c7 | Function assay | 12.5 uM | 24 hrs | Induction of quinone reductase activity in mouse Hepa 1c1c7 cells at 12.5 uM after 24 hrs relative to control, Activity=1.24μM. | 17316918 |
Hepa 1c1c7c1 | Function assay | 12.5 uM | 24 hrs | Induction of quinone reductase in mouse mutant Hepa 1c1c7c1 cells at 12.5 uM after 24 hrs relative to control, Activity=1.16μM. | 17316918 |
HUVEC | Function assay | 100 μM | 1 day | Induction of mitochondrial biogenesis in H2O2-induced HUVEC at 100 umol/L pretreated for 1 day followed by compound washout and H2O2-treatment measured after 10 days by MitoTracker Red staining-based assay | 23859249 |
MG63 | Function assay | 0.1 to 10 uM | 24 hr | Increase in proliferation of human MG63 cells at 0.1 to 10 uM after 24 hr by flow cytometry | 17513867 |
MC3T3-E1 | Function assay | 0.1 to 10 uM | 7 days | Increase in ALP activity in mouse MC3T3-E1 cells at 0.1 to 10 uM after 7 days | 17513867 |
primary osteoblast cells | Function assay | 0.1 to 10 uM | 7 days | Increase in ALP activity in rat primary osteoblast cells at 0.1 to 10 uM after 7 days | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 72 hrs | Increase in osteocalcin mRNA levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by RT-PCR | 17513867 |
MG63 | Function assay | 1 uM | 72 hrs | Increase in osteocalcin mRNA levels in human MG63 cells at 1 uM after 72 hrs by RT-PCR | 17513867 |
primary osteoblast cells | Function assay | 1 uM | 72 hrs | Increase in osteocalcin mRNA levels in rat primary osteoblast cells at 1 uM after 72 hrs by RT-PCR | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 72 hrs | Increase in osteocalcin levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by ELISA | 17513867 |
MG63 | Function assay | 1 uM | 72 hrs | Increase in osteocalcin levels in human MG63 cells at 1 uM after 72 hrs by ELISA | 17513867 |
primary osteoblast cells | Function assay | 1 uM | 72 hrs | Increase in osteocalcin levels in rat primary osteoblast cells at 1 uM after 72 hrs by ELISA | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 72 hrs | Increase in osteopontin mRNA levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by RT-PCR | 17513867 |
MG63 | Function assay | 1 uM | 72 hrs | Increase in osteopontin mRNA levels in human MG63 cells at 1 uM after 72 hrs by RT-PCR | 17513867 |
primary osteoblast cells | Function assay | 1 uM | 72 hrs | Increase in osteopontin mRNA levels in rat primary osteoblast cells at 1 uM after 72 hrs by RT-PCR | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 72 hrs | Increase in osteopontin levels in mouse MC3T3-E1 cells at 1 uM after 72 hrs by ELISA | 17513867 |
MG63 | Function assay | 1 uM | 72 hrs | Increase in osteopontin levels in human MG63 cells at 1 uM after 72 hrs by ELISA | 17513867 |
primary osteoblast cells | Function assay | 1 uM | 72 hrs | Increase in osteopontin levels in rat primary osteoblast cells at 1 uM after 72 hrs by ELISA | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 4 hrs | Increase in BMP2 expression in mouse MC3T3-E1 cells expressing pBMP2 mutant at 1 uM after 4 hrs by luciferase method relative to control | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 4 hrs | Increase in BMP2 expression in mouse MC3T3-E1 cells expressing pBMP2delta1 mutant at 1 uM after 4 hrs by luciferase method relative to control | 17513867 |
MDA-MB-231 | Function assay | 10 mg/kg | 2 days | Decrease in Akt activation in human MDA-MB-231 cells expressing FOXO3a-specific small interfering RNA xenografted in nude mice at 10 mg/kg for 2 days | 17513867 |
MDA-MB-231 | Function assay | 10 mg/kg | 2 days | Induction of FOXO3a nuclear accumulation in human MDA-MB-231 cells FOXO3a-specific small interfering RNA xenografted in nude mice at 10 mg/kg for 2 days | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 48 hrs | Inhibition of induction of ALP activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody | 17513867 |
primary osteoblast cells | Function assay | 1 uM | 48 hrs | Inhibition of induction of ALP activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody | 17513867 |
MC3T3-E1 | Function assay | 1 uM | 48 hrs | Inhibition of induction of ALP activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of noggin | 17513867 |
primary osteoblast cells | Function assay | 1 uM | 48 hrs | Inhibition of induction of ALP activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of noggin | 17513867 |
primary osteoblast cells | Antiapoptotic activity assay | 1 uM | 48 hrs | Inhibition of antiapoptotic activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody | 17513867 |
primary osteoblast cells | Antiapoptotic activity assay | 1 uM | 48 hrs | Inhibition of antiapoptotic activity in rat primary osteoblast cells at 1 uM after 48 hrs in presence of noggin | 17513867 |
MC3T3-E1 | Function assay | 0.1 to 10 uM | 24 hr | Increase in proliferation of mouse MC3T3-E1 cells assessed as fraction of cells in S phase at 0.1 to 10 uM after 24 hr by flow cytometry | 17513867 |
primary osteoblast cells | Function assay | 0.1 to 10 uM | 24 hr | Increase in proliferation of rat primary osteoblast cells at 0.1 to 10 uM after 24 hr by flow cytometry | 17513867 |
MG63 | Function assay | 0.1 to 10 uM | 7 days | Increase in ALP activity in human MG63 cells at 0.1 to 10 uM after 7 days | 17513867 |
MC3T3-E1 | Antiapoptotic activity assay | 1 uM | 48 hrs | Inhibition of antiapoptotic activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of BMP2-specific neutralizing antibody | 17513867 |
MC3T3-E1 | Antiapoptotic activity assay | 1 uM | 48 hrs | Inhibition of antiapoptotic activity in mouse MC3T3-E1 cells at 1 uM after 48 hrs in presence of noggin | 17513867 |
HEK293 | Function assay | 100 uM | 1 hr | Inhibition of heat killed Escherichia coli K12-induced nuclear translocation of p65 element of NF-kappaB in HEK293 cells expressing TLR2 at 100 uM pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by immunostaining method | 17938187 |
HEK293 | Function assay | 100 uM | 1 hr | Inhibition of heat killed Staphylococcus aureus 209P-induced nuclear translocation of p65 element of NF-kappaB in HEK293 cells expressing TLR2 at 100 uM pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by immunostaining method | 17938187 |
RAW264.7 | Function assay | 1 to 100 uM | 6 hrs | Inhibition of heat killed Escherichia coli K12-induced TNF alpha production in mouse RAW264.7 cells at 1 to 100 uM after 6 hrs by ELISA | 17938187 |
THP1 | Function assay | 1 to 100 uM | 6 hrs | Inhibition of heat killed Escherichia coli K12-induced TNF alpha production in human THP1 cells at 1 to 100 uM after 6 hrs by ELISA | 17938187 |
RAW264.7 | Function assay | 1 to 100 uM | 6 hrs | Inhibition of heat killed Staphylococcus aureus 209P-induced TNF alpha production in mouse RAW264.7 cells at 1 to 100 uM after 6 hrs by ELISA | 17938187 |
THP1 | Function assay | 1 to 100 uM | 6 hrs | Inhibition of heat killed Staphylococcus aureus 209P-induced TNF alpha production in human THP1 cells at 1 to 100 uM after 6 hrs by ELISA | 17938187 |
THP1 | Function assay | 100 uM | 1 hr | Inhibition of FSL1-induced upregulation of MSR1 mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR | 17938187 |
THP1 | Function assay | 100 uM | 1 hr | Inhibition of FSL1-induced upregulation of CD36 mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR | 17938187 |
THP1 | Function assay | 100 uM | 1 hr | Inhibition of FSL1-induced upregulation of DC-SIGN mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR | 17938187 |
THP1 | Function assay | 100 uM | 1 hr | Inhibition of FSL1-induced upregulation of dectin-1 mRNA expression in in human THP1 cells at 100 uM after 1 hr by RT-PCR | 17938187 |
HL60 | Function assay | 150 uM | 48 hrs | Induction of DNA fragmentation in human HL60 cells at 150 uM after 48 hrs by ethidium bromide based gel electrophoresis | 19271734 |
C2C12 | Function assay | 50 uM | 16 hrs | Increase in mitochondrial function in mouse C2C12 cells assessed as enhancement of mitochondrial density at 50 uM after 16 hrs by green FM dye straining-based fluorescence assay | 19663498 |
H460 | Cell cycle assay | 20 uM | 24 hrs | Cell cycle arrest in human H460 cells assessed as accumulation at G2/M phase at 20 uM after 24 hrs by propidium iodide staining-based flow cytometry | 20409723 |
RAW264.7 | Function assay | 34 uM | 15 mins | Inhibition of LPS-induced iNOS expression in mouse RAW264.7 cells at 34 uM treated 15 mins before LPS challenge measured after 18 hrs by Western blotting | 20527891 |
CCD-18Co | Antiinflammatory assay | 1 uM | 18 hrs | Antiinflammatory activity in human CCD-18Co cells assessed inhibition of IL1beta-induced PGE2 production at 1 uM after 18 hrs | 20866032 |
CCD-18Co | Antiinflammatory assay | 2.5 to 25 uM | 18 hrs | Antiinflammatory activity in human CCD-18Co cells assessed as inhibition of IL1beta-induced PGE2 production at 2.5 to 25 uM after 18 hrs | 20866032 |
SW480 | Cytotoxicity assay | 10 uM | 2 days | Cytotoxicity against human SW480 cells at 10 uM for 2 days by vi-cell cell viability analysis | 21291235 |
HCT116 | Cytotoxicity assay | 10 uM | 2 days | Cytotoxicity against human HCT116 cells at 10 uM for 2 days by vi-cell cell viability analysis | 21291235 |
HCT116 | Cytotoxicity assay | 10 uM | 4 days | Cytotoxicity against human HCT116 cells at 10 uM for 4 days by vi-cell cell viability analysis | 21291235 |
LS 174T | Cytotoxicity assay | 10 uM | 4 days | Cytotoxicity against human LS 174T cells at 10 uM for 4 days by vi-cell cell viability analysis | 21291235 |
LS 174T | Cytotoxicity assay | 10 uM | 2 days | Cytotoxicity against human LS 174T cells at 10 uM for 2 days by vi-cell cell viability analysis | 21291235 |
LS174T | Function assay | 100 uM | 36 hrs | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in Ki67 mRNA level at 100 uM after 36 hrs by RT-PCR analysis | 21291235 |
LS174T | Function assay | 100 uM | 36 hrs | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in c-Myc mRNA level at 100 uM after 36 hrs by RT-PCR analysis | 21291235 |
LS174T | Function assay | 100 uM | 36 hrs | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in CD44 mRNA level at 100 uM after 36 hrs by RT-PCR analysis | 21291235 |
LS174T | Function assay | 100 uM | 36 hrs | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in Lgr5 mRNA level at 100 uM after 36 hrs by RT-PCR analysis | 21291235 |
LS174T | Function assay | 100 uM | 36 hrs | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in survivin mRNA level at 100 uM after 36 hrs by RT-PCR analysis | 21291235 |
HEK293T | Function assay | 100 uM | 12 hrs | Inhibition of LiCl-induced Wnt/beta-casein in human HEK293T cells transfected with TOP Flash assessed as decrease in luciferase expression at 100 uM after 12 hrs by dual luciferase reporter assay | 21291235 |
SW480 | Cytotoxicity assay | 10 uM | 4 days | Cytotoxicity against human SW480 cells at 10 uM for 4 days by vi-cell cell viability analysis | 21291235 |
HEK293T | Function assay | 100 uM | 12 hrs | Inhibition of Wnt/beta-casein in human HEK293T cells transfected with TOP Flash assessed as decrease in luciferase expression at 100 uM after 12 hrs by dual luciferase reporter assay | 21291235 |
32Dcl3 | Function assay | 10 uM | 1 hr | Radioprotective activity against 0 to 7 Gy gamma radiation-induced death in mouse 32Dcl3 cells at 10 uM treated 1 hr prior to irradiation after 7 days by microscopy | 21826253 |
RAW264.7 | Antiinflammatory assay | 50 uM | 1.5 hrs | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha production at 50 uM after 1.5 hrs by ELISA | 22088309 |
B16F10 | Antimelanogenic assay | 200 uM | 72 hrs | Antimelanogenic activity in mouse assessed as cellular melanin content B16F10 cells at 200 uM after 72 hrs spectrophotometric analysis | 22189272 |
SH-SY5Y | Neuroprotective assay | 10 uM | 24 hrs | Neuroprotective activity in human SH-SY5Y cells assessed as inhibition H2O2-induced reduction of cell viability at 10 uM after 24 hrs by phase-contrast micrograph analysis | 24269515 |
HeLa | Function assay | 10 to 100 uM | 24 hrs | Induction of SV40 promoter-mediated luciferase gene expression in human HeLa cells at 10 to 100 uM after 24 hrs by RT-PCR analysis | 25147604 |
RAW264.7 | Anti-inflammatory assay | 10 mM | 10 mins | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced IL6 production at 10 mM pre-incubated for 10 mins before LPS stimulation for 24 hrs by ELISA method | 26048788 |
RAW264.7 | Anti-inflammatory assay | 10 mM | 10 mins | Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha production at 10 mM pre-incubated for 10 mins before LPS stimulation for 24 hrs by ELISA method | 26048788 |
HaCaT | Function assay | 1 uM | 1 hr | Activation of SIRT1 in human HaCaT cells assessed as H4K16 deacetylation at 1 uM after 1 hr by Western blotting method | 26689352 |
U373-MAGI | Antiviral assay | 50 uM | 2 hrs | Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 50 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection measu, EC50=10μM. | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 4 hrs | Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 50 uM incubated for 4 hrs prior to viral infection measured at 72 hrs post infection by flow cytometric analysis | 27117260 |
U373-MAGI | Function assay | 200 uM | 6 hrs | Reduction in dGTP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis | 27117260 |
U373-MAGI | Function assay | 200 uM | 6 hrs | Reduction in dTTP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis | 27117260 |
U373-MAGI | Antiviral assay | 25 to 100 uM | 2 hrs | Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 25 to 100 uM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequ | 27117260 |
U373-MAGI | Function assay | 200 uM | 6 hrs | Reduction in dCTP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis | 27117260 |
U373-MAGI | Function assay | 50 uM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis | 27117260 |
U373-MAGI | Function assay | 200 uM | 6 hrs | Reduction in dATP level in human U373-MAGI cells at 200 uM after 6 hrs by LC-MS/MS analysis | 27117260 |
U373-MAGI | Function assay | 200 uM | 2 hrs | Reduction in dRGU-TP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis | 27117260 |
U373-MAGI | Function assay | 50 uM | 2 hrs | Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
U373-MAGI | Function assay | 200 uM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 2 to 72 hrs | Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 50 uM after 2 to 72 hrs by qPCR method | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 6 hrs | Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 50 uM measured at 6 hrs post infection by qPCR method | 27117260 |
U373-MAGI | Function assay | 200 uM | 2 hrs | Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
U373-MAGI | Function assay | 200 uM | 2 hrs | Reduction in 5-aza-dCTP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 2 to 8 hrs | Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 50 uM preincubated for 2 to 8 hrs followed by 5-Aza-C addition for 2 hrs and subsequen | 27117260 |
U373-MAGI | Antiviral assay | 25 uM | 2 hrs | Potentiation of 5-Aza-dC-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity at 25 uM preincubated for 2 hrs followed by 5-Aza-dC addition for 2 hrs and subsequent v | 27117260 |
U373-MAGI | Function assay | 50 uM | 2 hrs | Increase in 5-aza-dCTP/dCTP ratio in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-C addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-C | 27117260 |
U373-MAGI | Function assay | 50 uM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 50 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
U373-MAGI | Function assay | 200 uM | 2 hrs | Reduction in dCTP level in human U373-MAGI cells at 200 uM preincubated for 2 hrs followed by 5-aza-dC addition measured after 4 hrs by LC-MS/MS analysis relative to 5-aza-dC | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 2 to 72 hrs | Potentiation of 5-Aza-dC-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 50 uM after 2 to 72 hrs by qPCR method | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 2 to 72 hrs | Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 50 uM after 2 to 72 hrs by qPCR method | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 2 to 72 hrs | Potentiation of 5-Aza-dC-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in gag level at 50 uM after 2 to 72 hrs by qPCR method | 27117260 |
U373-MAGI | Antiviral assay | 50 uM | 6 hrs | Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in U5-gag level at 50 uM measured at 6 hrs post infection by qPCR method | 27117260 |
HCT116 | Cytotoxicity assay | 100 uM | 48 hrs | Cytotoxicity against human HCT116 cells assessed as cell growth inhibition at 100 uM after 48 hrs by MTT assay | 27887843 |
Bel7402 | Cytotoxicity assay | 100 uM | 48 hrs | Cytotoxicity against human Bel7402 cells assessed as cell growth inhibition at 100 uM after 48 hrs by MTT assay | 27887843 |
A375 | Function assay | 25 uM | 24 hrs | Inhibition of alpha-MSH-induced TRP-1 expression in human A375 cells at 25 uM after 24 hrs by Western blot method | 29150333 |
A375 | Function assay | 25 uM | 24 hrs | Inhibition of alpha-MSH-induced TRP-2 expression in human A375 cells at 25 uM after 24 hrs by Western blot method | 29150333 |
A375 | Function assay | 25 uM | 4 hrs | Inhibition of alpha-MSH-induced reactive oxygen species generation in human A375 cells at 25 uM after 4 hrs by DCFDA staining-based fluorescence assay | 29150333 |
3T3L1 | Function assay | 1 to 10 uM | 6 days | Inhibition of triglyceride accumulation in mouse 3T3L1 cells at 1 to 10 uM after 6 days by ORO staining-based microscopic method | 29172079 |
RAW264.7 | Function assay | 10 uM | 24 hrs | Inhibition of LPS-induced TNF-alpha production in rat RAW264.7 cells at 10 uM after 24 hrs by ELISA | 29407944 |
RAW264.7 | Function assay | 10 uM | 24 hrs | Inhibition of LPS-induced IL-6 production in rat RAW264.7 cells at 10 uM after 24 hrs by ELISA | 29407944 |
BV2 | Antineuroinflammatory assay | 10 to 30 uM | 24 hrs | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production at 10 to 30 uM after 24 hrs by Griess assay | 30096650 |
T cells | Antiproliferative assay | 50 uM | 1 hr | Antiproliferative activity against Con-A-induced T cells isolated from splenocytes of C57/BL6 mouse at 50 uM incubated with Con-A for 1 hr followed by compound addition measured after 72 hrs by MTT assay | 30193941 |
B cells | Antiproliferative assay | 50 uM | 1 hr | Antiproliferative activity against LPS-induced B cells isolated from splenocytes of C57/BL6 mouse at 50 uM incubated with LPS for 1 hr followed by compound addition measured after 72 hrs by MTT assay | 30193941 |
RAW264.7 | Immunomodulatory assay | 50 uM | 1 hr | Immunomodulatory activity in LPS-stimulated mouse RAW264.7 cells assessed as decrease in CD80 expression at 50 uM incubated with LPS for 1 hr followed by compound addition measured after 24 hrs by flow cytometry | 30193941 |
RAW264.7 | Immunomodulatory assay | 50 uM | 1 hr | Immunomodulatory activity in LPS-stimulated mouse RAW264.7 cells assessed as decrease in CD86 expression at 50 uM incubated with LPS for 1 hr followed by compound addition measured after 24 hrs by flow cytometry | 30193941 |
HBZY-1 | Function assay | 6 uM | 24 hrs | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in NQO-1 mRNA expression at 6 uM after 24 hrs by RT-PCR analysis | 30408749 |
HBZY-1 | Function assay | 6 uM | 24 hrs | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in HO-1 mRNA expression at 6 uM after 24 hrs by RT-PCR analysis | 30408749 |
HBZY-1 | Function assay | 6 uM | 24 hrs | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLM mRNA expression at 6 uM after 24 hrs by RT-PCR analysis | 30408749 |
HBZY-1 | Function assay | 6 uM | 24 hrs | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLC mRNA expression at 6 uM after 24 hrs by RT-PCR analysis | 30408749 |
BV2 | Antineuroinflammatory assay | 30 mins | 24 hrs | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pretreated for 30 mins followed by LPS-stimulation for 24 hrs by Griess assay, IC50=11.1μM. | 30771601 |
MCF7 | Antioxidant assay | 100 uM | 24 hrs | Antioxidant activity in human MCF7 cells assessed as decrease in reactive oxygen species generation at 100 uM incubated for 24 hrs by CellROX green/Hoechst 33342 staining based assay | 30921758 |
RAW264.7 | Antiinflammatory assay | 10 uM | 1 hr | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM pretreated for 1 hr followed by LPS stimulation and measured after 24 hrs by Griess reagent based assay | 31077997 |
H9c2 | Antioxidant assay | 80 nM to 2 uM | 18 hrs | Antioxidant activity in rat H9c2 cells assessed as reduction in hypoxia-induced NO release at 80 nM to 2 uM preincubated for 18 hrs followed by incubated in hypoxia for 48 hrs by griess assay | 31351395 |
H9c2 | Antioxidant assay | 2 uM | 18 hrs | Antioxidant activity in rat H9c2 cells assessed as increase in hypoxia-induced reduction of MnSOD expression at 2 uM preincubated for 18 hrs followed by incubated in hypoxia for 48 hrs by Western blot analysis | 31351395 |
HuH7 | Apoptosis assay | 100 uM | 48 hrs | Induction of apoptosis in human HuH7 cells transfected with ShSGK1 assessed as late apoptosis at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay | 31539779 |
HUH7 | Function assay | 100 uM | 6 hrs | Inhibition of insulin-induced SGK1 in human HUH7 cells at 100 uM using peptide as substrate incubated for 6 hrs by scintillation counter method | 31539779 |
HuH7 | Function assay | 100 uM | 6 hrs | Inhibition of SGK1 in human HuH7 cells assessed as reduction in insulin-induced MDM2 phosphorylation on Ser166 at 100 uM incubated for 6 hrs by Western blot analysis | 31539779 |
HuH7 | Antiproliferative assay | 100 uM | 48 hrs | Antiproliferative activity against human HuH7 cells assessed as reduction in cell viability at 100 uM incubated for 48 hrs by trypan blue dye based assay | 31539779 |
HuH7 | Apoptosis assay | 100 uM | 48 hrs | Induction of apoptosis in human HuH7 cells assessed as increase in early apoptotic cells at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay | 31539779 |
HuH7 | Apoptosis assay | 100 uM | 48 hrs | Induction of apoptosis in human HuH7 cells assessed as increase in late apoptotic cells at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay | 31539779 |
HuH7 | Apoptosis assay | 100 uM | 48 hrs | Induction of apoptosis in human HuH7 cells assessed as increase in necrotic cells at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay | 31539779 |
HuH7 | Antiproliferative assay | 100 uM | 48 hrs | Antiproliferative activity against human HuH7 cells transfected with ShSGK1 assessed as reduction in cell viability at 100 uM incubated for 48 hrs by trypan blue dye based assay | 31539779 |
HuH7 | Antiproliferative assay | 100 uM | 48 hrs | Antiproliferative activity against human HuH7 cells overexpressing EGFP assessed as reduction in cell viability at 100 uM incubated for 48 hrs by trypan blue dye based assay | 31539779 |
HuH7 | Apoptosis assay | 100 uM | 48 hrs | Induction of apoptosis in human HuH7 cells transfected with ShSGK1 assessed as early apoptosis at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay | 31539779 |
HuH7 | Apoptosis assay | 100 uM | 48 hrs | Induction of apoptosis in human HuH7 cells overexpressing EGFP at 100 uM incubated for 48 hrs by annexin V and 7-AAD staining based assay | 31539779 |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in ER.DNA complex in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM by RT-PCR | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in Src kinase phosphorylation in mouse MC3T3-E1 cells at 1 uM in presence of PP2 | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in Src kinase phosphorylation in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Increase in Src kinase phosphorylation in mouse MC3T3-E1 cells at 1 uM | 17513867 | |
T47D | Antiproliferative assay | 1 uM | Antiproliferative activity against human T47D cells at 1 uM by flow cytometry | 17513867 | |
primary osteoblast cells | Function assay | 1 uM | Reversal of increase in ER.DNA complex in rat primary osteoblast cells transfected with dominant-negative mutant Src expression vector at 1 uM by RT-PCR | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in pBMP2 expression in mouse MC3T3-E1 cells at 1 uM by luciferase method in presence of PP2 | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Induction of ER association with BMP2 promoter in mouse MC3T3-E1 cells at 1 uM by ChiP assay | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of induction in nuclear translocation of ERalpha in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM | 17513867 | |
MCF7 | Antiproliferative assay | 1 uM | Antiproliferative activity against human MCF7 cells at 1 uM by flow cytometry | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in pBMP2 expression in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM by luciferase method | 17513867 | |
MCF7 | Function assay | 1 uM | Reduction in anchorage-independent colony formation of human MCF7 cells at 1 uM by soft agar colony forming assay | 17513867 | |
T47D | Function assay | 1 uM | Reduction in anchorage-independent colony formation of human T47D cells at 1 uM by soft agar colony forming assay | 17513867 | |
primary osteoblast cells | Function assay | 1 uM | Increase in BMP2 mRNA levels in rat primary osteoblast cells at 1 uM by RT-PCR method | 17513867 | |
primary osteoblast cells | Function assay | 1 uM | Reversal of increase in ER.DNA complex in rat primary osteoblast cells at 1 uM by RT-PCR in presence of PP2 | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of induction of BMP2 expression in mouse MC3T3-E1 cells at 1 uM by Western blot in presence of ICI-182780 | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of induction of BMP2 expression in mouse MC3T3-E1 cells at 1 uM by Western blot in presence of short interfering ERalpha-RNA | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of induction in nuclear translocation of ERalpha in mouse MC3T3-E1 cells at 1 uM in presence of PP2 | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of induction in BMP2 expression in mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector at 1 uM by Western blot | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of induction in BMP2 expression in mouse MC3T3-E1 cells at 1 uM by Western blot in presence of PP2 | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in ER.DNA complex in mouse MC3T3-E1 cells at 1 uM by RT-PCR in presence of PP2 | 17513867 | |
primary osteoblast cells | Function assay | 1 uM | Reversal of increase in pBMP2 expression in rat primary osteoblast cells transfected with dominant-negative mutant Src expression vector at 1 uM by luciferase method | 17513867 | |
primary osteoblast cells | Function assay | 1 uM | Reversal of increase in pBMP2 expression in rat primary osteoblast cells at 1 uM by luciferase method in presence of PP2 | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in BMP2 expression in mouse MC3T3-E1 cells expressing small interfering RNA for FOXA1 protein at 1 uM by Western blot | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in pBMP2 expression in mouse MC3T3-E1 cells expressing small interfering RNA for FOXA1 protein at 1 uM by luciferase method | 17513867 | |
MC3T3-E1 | Function assay | 1 uM | Reversal of increase in ER.DNA complex in mouse MC3T3-E1 cells expressing small interfering RNA for FOXA1 protein at 1 uM by RT-PCR | 17513867 | |
MDA-MB-231 | Antiproliferative assay | 1 uM | Antiproliferative activity against human MDA-MB-231 cells at 1 uM by flow cytometry | 17513867 | |
MDA-MB-231 | Function assay | 1 uM | Reduction in anchorage-independent colony formation of human MDA-MB-231 cells at 1 uM by soft agar colony forming assay | 17513867 | |
HEK293 | Function assay | 100 uM | Inhibition of DC-SIGN expression in HEK293 cells expressing DC-SIGN at 100 uM by Western blot analysis | 17938187 | |
U2OS | Function assay | 100 uM | Activation of SIRT1 in human U2OS cells assessed as decrease in p53 deacetylation level at 100 uM | 18046409 | |
PBL | Function assay | 12.5 uM | Inhibition of hydrogen peroxide-induced DNA damage in human PBL cells at 12.5 uM by Comet assay | 19271734 | |
LS174T | Function assay | 100 uM | Inhibition of Wnt/beta-casein in human LS174T cells assessed as increase in p21WAF1/CIP1 protein level at 100 uM by Western blotting | 21291235 | |
LS174T | Function assay | 100 uM | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in cyclin B1 protein level at 100 uM by Western blotting | 21291235 | |
LS174T | Function assay | 100 uM | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in c-Myc protein level at 100 uM by Western blotting | 21291235 | |
LS174T | Function assay | 100 uM | Inhibition of Wnt/beta-casein in human LS174T cells assessed as reduction in Cyclin D1 protein level at 100 uM by Western blotting | 21291235 | |
LS 174T | Function assay | 100 uM | Inhibition of Wnt/beta-casein in human LS 174T cells assessed as reduction in TCF4 protein level at 100 uM by Western blotting | 21291235 | |
LS 174T | Function assay | 100 uM | Inhibition of Wnt/beta-casein in human LS 174T cells assessed as reduction in pygopus2 protein level at 100 uM by Western blotting | 21291235 | |
MCF7 | Function assay | >100 uM | Activation of SIRT1 in human MCF7 cells assessed as reduction in doxorubicin-induced acetyl-p53 level at >100 uM after 6 hrs by Western blotting analysis | 23316803 | |
HBZY-1 | Function assay | 6 uM | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in NQO-1 level at 6 uM by Western blot analysis | 30408749 | |
HBZY-1 | Function assay | 6 uM | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in HO-1 level at 6 uM by Western blot analysis | 30408749 | |
HBZY-1 | Function assay | 6 uM | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLM level at 6 uM by Western blot analysis | 30408749 | |
HBZY-1 | Function assay | 6 uM | Activation of Nrf2 in rat HBZY-1 cells assessed as increase in GCLC level at 6 uM by Western blot analysis | 30408749 | |
HBZY-1 | Function assay | 6 uM | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in NQO-1 mRNA expression at 6 uM by RT-PCR analysis | 31301564 | |
HBZY-1 | Function assay | 6 uM | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in HO-1 mRNA expression at 6 uM by RT-PCR analysis | 31301564 | |
HBZY-1 | Function assay | 6 uM | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLM mRNA expression at 6 uM by RT-PCR analysis | 31301564 | |
HBZY-1 | Function assay | 6 uM | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLC mRNA expression at 6 uM by RT-PCR analysis | 31301564 | |
MCF7 | Function assay | 6 hrs | Inhibition of phorbol ester-induced ornithine decarboxylase in human MCF7 cells after 6 hrs, IC50=19μM. | 10075742 | |
Hepa1clc7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse Hepa1clc7 cells after 72 hrs, IC50=11μM. | 10075742 | |
MC3T3-E1 | Function assay | 24 hrs | Inhibition of TNF-alpha-induced apoptosis in mouse MC3T3-E1 cells after 24 hrs by flow cytometry | 17513867 | |
primary osteoblast cells | Function assay | 24 hrs | Inhibition of etoposide-induced apoptosis in rat primary osteoblast cells after 24 hrs by flow cytometry | 17513867 | |
primary osteoblast cells | Function assay | 24 hrs | Inhibition of TNF-alpha-induced apoptosis in rat primary osteoblast cells after 24 hrs by flow cytometry | 17513867 | |
MC3T3-E1 | Function assay | 24 hrs | Inhibition of etoposide-induced apoptosis in mouse MC3T3-E1 cells after 24 hrs by flow cytometry | 17513867 | |
THP1 | Function assay | 1 hr | Inhibition of FSL-1-induced increase in phagocytosis of FITC-conjugated Escherichia coli K12 in human THP1 cells assessed as reduction in number of cells phagocytosing bacteria per cell after 1 hr by CLSM | 17938187 | |
THP1 | Function assay | 1 hr | Inhibition of FSL-1-induced increase in phagocytosis of FITC-conjugated Escherichia coli K12 in human THP1 cells assessed as reduction in number of phagocytosing bacteria to total number of cells after 1 hr by CLSM | 17938187 | |
HEK293 | Function assay | 1 hr | Inhibition of heat killed Escherichia coli K12-induced NF-kappaB activation in HEK293 cells expressing TLR2 pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by luciferase reporter gene assay | 17938187 | |
HEK293 | Function assay | 1 hr | Inhibition of heat killed Staphylococcus aureus 209P-induced NF-kappaB activation in HEK293 cells expressing TLR2 pretreated for 1 hr before 6 hrs heat killed bacterial stimulation by luciferase reporter gene assay | 17938187 | |
293 | Function assay | 24 hrs | Inhibition of TNFalpha induced NF-kappaB activation in human 293 cells after 24 hrs by luciferase reporter gene assay, IC50=16.1μM. | 18487053 | |
cortical microglial | Function assay | 48 hrs | Inhibition of LPS-stimulated NO release in rat cortical microglial cells assessed as nitrite accumulation after 48 hrs, IC50=11.5μM. | 18588343 | |
HL60 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60 cells after 48 hrs by MTT assay, IC50=36.3μM. | 19251420 | |
DLKP | Antiproliferative assay | 5 days | Antiproliferative activity against MRP1-expressing human DLKP cells after 5 days by acid phosphatase assay, IC50=10μM. | 19481462 | |
DLKP-A | Antiproliferative assay | 5 days | Antiproliferative activity against P-gp expressing human DLKP-A cells after 5 days by acid phosphatase assay, IC50=15μM. | 19481462 | |
HT144 | Antiproliferative assay | 5 days | Antiproliferative activity against human HT144 cells after 5 days by acid phosphatase assay, IC50=40μM. | 19481462 | |
3T3L1 | Antiadipogenic assay | 7 days | Antiadipogenic activity against mouse 3T3L1 cells assessed as inhibition of differentiation after 7 days by oil-red O staining, IC50=31.4μM. | 19757853 | |
SW480 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SW480 cells assessed as cell viability using propidium iodide staining after 48 hrs, IC50=20μM. | 20395019 | |
H460 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human H460 cells after 72 hrs, IC50=12.9μM. | 20409723 | |
HEK293 | Function assay | 48 hrs | Inhibition of TNF-alpha-induced NF-kappaB activity expressed in HEK293 cells after 48 hrs by luciferase reporter gene assay, IC50=0.173μM. | 20527891 | |
RAW 264.7 | Function assay | 20 hrs | Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells pretreated 30 mins before LPS challenge measured after 20 hrs by Griess reaction method relative to control, IC50=15μM. | 20527891 | |
Caco-2 | Cytotoxicity assay | 3 days | Cytotoxicity against human Caco-2 cells after 3 days by [3H]thymidine incorporation assay, IC50=24.35μM. | 20627379 | |
HT-29 | Cytotoxicity assay | 3 days | Cytotoxicity against human HT-29 cells after 3 days by [3H]thymidine incorporation assay, IC50=45.3μM. | 20627379 | |
MDA-MB-231 | Antitumor assay | 6 days | Antitumor activity against human MDA-MB-231 cells after 6 days by SRB assay, IC50=20.5μM. | 20728369 | |
Caco2 | Function assay | 6 hrs | Metabolic stability in human Caco2 cells after 6 hrs by LC-MS-MS analysis | 20866032 | |
HT22 | Neuroprotective assay | 24 hrs | Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxytosis after 24 hrs by MTT assay, EC50=4.667μM. | 21129978 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000225μM. | 21851083 | |
SK-N-SH | Antiproliferative assay | 48 hrs | Antiproliferative activity against human SK-N-SH cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000403μM. | 21851083 | |
A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000447μM. | 21851083 | |
MCF7 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MCF7 cells assessed as cell viability after 48 hrs by SRB assay, IC50=0.0000791μM. | 21851083 | |
RAW264.7 | Antiinflammatory assay | 30 mins | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins before LPS challenge measured after 24 hrs by Griess method, IC50=30.71μM. | 22115839 | |
RAW264.7 | Function assay | 18 hrs | Inhibition of iNOS in LPS-stimulated mouse RAW264.7 cells after 18 hrs, IC50=23.2μM. | 22386564 | |
RAW264.7 | Antiinflammatory assay | 30 mins | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production preincubated for 30 mins measured 24 hrs post LPS challenge by Griess method, IC50=30.71μM. | 22386564 | |
NIH/3T3 | Cytotoxicity assay | 96 hrs | Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay, IC50=24.22μM. | 22749392 | |
Hepa-1c1c7 | Function assay | 48 hrs | Induction of quinone reductase-1 activity in mouse Hepa-1c1c7 cells after 48 hrs by MTT assay, CD=21μM. | 23142320 | |
RAW 264.7 | Function assay | 30 mins | Inhibition of LPS-induced iNOS activity in mouse RAW 264.7 cells assessed as inhibition of NO production pretreated with compound for 30 mins before LPS challenge after 24 hrs by Griess reagent method, IC50=23.2μM. | 23142320 | |
HL60 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HL60 cells assessed as growth inhibition measured after 48 hrs by XTT assay, IC50=31.8μM. | 23547843 | |
SK-MEL | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SK-MEL cells assessed as growth inhibition measured after 48 hrs by XTT assay, IC50=47.3μM. | 23547843 | |
Huh7.5.1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Huh7.5.1 cells after 72 hrs, IC50=10.6μM. | 23673225 | |
MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human estrogen receptor positive MCF7 cells after 72 hrs by MTT assay, IC50=28.07μM. | 23860590 | |
SKBR3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human estrogen receptor negative SKBR3 cells after 72 hrs by MTT assay, IC50=41.42μM. | 23860590 | |
ScN2a-cl3 | Function assay | 5 days | Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by Western blotting analysis, EC50=0.58μM. | 24183589 | |
ScN2a-cl3 | Function assay | 5 days | Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA, EC50=3.06μM. | 24183589 | |
HEK293 | Function assay | 6 hrs | Inhibition of TNF-alpha-induced NF-kappaB activity in HEK293 cells after 6 hrs by luciferase reporter gene assay, IC50=2.5μM. | 24992702 | |
Hepa-1c1c7 | Function assay | 48 hrs | Induction of quinone reductase 1 in mouse Hepa-1c1c7 cells after 48 hrs by MTT assay, CD=21μM. | 24992702 | |
HeLa | Antiproliferative assay | 48 hrs | Antiproliferative activity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay, IC50=47.9μM. | 25817772 | |
U373-MAGI | Antiviral assay | 2 to 8 hrs | Antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as reduction in viral infectivity preincubated for 2 to 8 hrs followed by viral infection measured at 72 hrs post infection by flow cytometric analysis | 27117260 | |
DH5aplha | Function assay | 2 mins | Inhibition of recombinant human CYP1A1 expressed in Escherichia coli DH5aplha cells assessed as O-deethylation of ethoxyresorufin in presence of NADPH measured after 2 mins by spectrofluorometric method, IC50=34μM. | 27265259 | |
MDAH 2774 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MDAH 2774 cells after 72 hrs by MTT assay, CD50=14.6μM. | 27515319 | |
T24 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human T24 cells after 72 hrs by MTT assay, CD50=22.7μM. | 27515319 | |
MDAH 2774 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDAH 2774 cells after 48 hrs by MTT assay, CD50=23μM. | 27515319 | |
DU145 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human DU145 cells after 72 hrs by MTT assay, CD50=27.9μM. | 27515319 | |
MHRF | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MHRF cells after 72 hrs by MTT assay, CD50=32μM. | 27515319 | |
MDAH 2774 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human MDAH 2774 cells after 24 hrs by MTT assay, CD50=36.9μM. | 27515319 | |
HepG2 | Function assay | 5 hrs | Activation of Nrf2 (unknown origin) expressed in human HepG2 cells after 5 hrs by ARE-driven luciferase reporter gene assay, EC50=5.4μM. | 28126440 | |
HEK293 | Growth inhibition assay | 2 days | Growth inhibition of HEK293 cells after 2 days by MTT assay, IC50=17μM. | 28408224 | |
MCF7 | Growth inhibition assay | 2 days | Growth inhibition of human MCF7 cells after 2 days by MTT assay, IC50=34μM. | 28408224 | |
Ramos | Growth inhibition assay | 2 days | Growth inhibition of human Ramos cells after 2 days by MTT assay, IC50=37μM. | 28408224 | |
ALL5 | Cytotoxicity assay | 120 hrs | Cytotoxicity against human ALL5 cells after 120 hrs by MTT method, IC50=10.5μM. | 28499732 | |
LN229 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=11μM. | 28654265 | |
NCI-H460 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM. | 28654265 | |
MML1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM. | 28654265 | |
BxPC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=14μM. | 28654265 | |
SK-MEL-2 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=14μM. | 28654265 | |
MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=15μM. | 28654265 | |
A549 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=16μM. | 28654265 | |
U87 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=20μM. | 28654265 | |
T47D | Cytotoxicity assay | 48 hrs | Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=25μM. | 28654265 | |
HT-29 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=27μM. | 28654265 | |
COLO201 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=37μM. | 28654265 | |
PANC1 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PANC1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=39μM. | 28654265 | |
BV2 | Antineuroinflammatory assay | 24 hrs | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay, IC50=18.66μM. | 28911817 | |
HEK293T | Cytotoxicity assay | 24 hrs | Cytotoxicity against HEK293T cells after 24 hrs by MTT assay, CC50=22.75μM. | 29172079 | |
BV2 | Antineuroinflammatory assay | 24 hrs | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced IL-1beta production after 24 hrs by ELISA, IC50=8.7μM. | 29499485 | |
BV2 | Antineuroinflammatory assay | 24 hrs | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced TNFalpha production after 24 hrs by ELISA, IC50=9.5μM. | 29499485 | |
BV2 | Antineuroinflammatory assay | 30 mins | Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production pretreated for 30 mins followed by LPS stimulation and measured after 24 hrs by Griess assay, IC50=11.1μM. | 29499485 | |
J774 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced IL6 expression after 24 hrs by ELISA, IC50=6.8μM. | 29726680 | |
J774 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50=12.15μM. | 29726680 | |
J774 | Antiinflammatory assay | 24 hrs | Antiinflammatory activity in mouse J774 cells assessed as reduction in LPS-induced MCP1 expression after 24 hrs by ELISA, IC50=13.6μM. | 29726680 | |
RAW 264.7 | Function assay | 24 hrs | Inhibition of NFkappaB in mouse RAW 264.7 cells assessed as reduction in LPS induced NO production after 24 hrs in presence of OBHS by Griess assay, IC50=11μM. | 30053783 | |
RAW 264.7 | Function assay | 24 hrs | Inhibition of NFkappaB in mouse RAW 264.7 cells assessed as reduction in LPS induced NO production after 24 hrs by Griess assay, IC50=13.1μM. | 30053783 | |
MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay, IC50=22.9μM. | 30053783 | |
MCF7 | Antiproliferative assay | 72 hrs | Antiproliferative activity against human MCF7 cells after 72 hrs in presence of OBHS by MTT assay, IC50=25.4μM. | 30053783 | |
RAW264.7 | Antiinflammatory assay | 1 hr | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO levels incubated with LPS/IFNgamma for 1 hr followed by compound addition measured after 48 hrs by Griess assay (Rvb = 55 +/- 2., Activity=44.5μM. | 30193941 | |
RAW264.7 | Antiinflammatory assay | 2 hrs | Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS/IFNgamma-induced NO production by measuring NO level preincubated for 2 hrs and followed by LPS/IFNgamma addition and measured after 24 hrs by Griess assay, IC50=44.1μM. | 31350127 | |
PMNL | Function assay | 15 mins | Inhibition of 5-LOX in human PMNL cells assessed as A23187-stimulated LTB4 production preincubated for 15 mins followed by A23187 addition and measured after 10 mins by HPLC analysis, IC50=4.9μM. | 31351395 | |
TOV112D | Cytotoxicity assay | 96 hrs | Cytotoxicity against human TOV112D cells transfected with empty vector assessed as reduction in cell viability incubated for 96 hrs by MTT assay, IC50=10.67μM. | 31514018 | |
TOV112D | Cytotoxicity assay | 96 hrs | Cytotoxicity against human TOV112D cells expressing NQO2 assessed as reduction in cell viability incubated for 96 hrs by MTT assay, IC50=11μM. | 31514018 | |
SKOV3 | Cytotoxicity assay | 96 hrs | Cytotoxicity against human SKOV3 cells transfected with non-targeted vector assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay, IC50=29μM. | 31514018 | |
SKOV3 | Cytotoxicity assay | 96 hrs | Cytotoxicity against human SKOV3 cells assessed as reduction in cell viability incubated for 96 hrs by MTT assay, IC50=36.3μM. | 31514018 | |
SKOV3 | Cytotoxicity assay | 96 hrs | Cytotoxicity against human SKOV3 cells transfected with shRNA assessed as reduction in cell viability incubated for 96 hrs in presence of doxycycline by MTT assay, IC50=39.67μM. | 31514018 | |
RAW 264.7 | Function assay | Inhibition of LPS and TNF-alpha-activated NO production in murine RAW 264.7 cells, IC50=23.5μM. | 17253844 | ||
BV2 | Function assay | Suppression of LPS-stimulated COX2 mRNA expression in mouse BV2 cells at 20 uM | 17125270 | ||
HEK293T | Function assay | Inhibition of TNF-alpha-induced NF-kappaB activation in HEK293T cells, IC50=20μM. | 17125270 | ||
HL60 | Antiproliferative assay | Antiproliferative activity against human HL60 cells, IC50=5μM. | 16580204 | ||
U937 | Cytotoxicity assay | Cytotoxicity against human U937 cells after 48 hrs by WST1 test, IC50=17μM. | 16252924 | ||
MDA-MB-231 | Antiproliferative assay | Inhibitory concentration required for antiproliferative activity against human MDA-MB-231 cells, IC50=20.5μM. | 16250636 | ||
MCF7 | Function assay | Estrogenic activity in human MCF7 cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by alamar blue assay, Activity=1.6μM. | 15787436 | ||
T47D | Function assay | Estrogenic activity in human T47D cells assessed as drug level causing stimulation of cell proliferation equivalent to 10 pM estradiol by alamar blue assay, Activity=0.03μM. | 15787436 | ||
RAW264.7 | Function assay | inhibitory concentration against PGE-2 production in LPS-stimulated RAW264.7 cells, IC50=20.8μM. | 15501064 | ||
RAW264.7 | Function assay | Inhibitory effect on PGE-2 production in LPS-stimulated RAW264.7 cells, IC50=4μM. | 15080988 | ||
RAW264.7 | Function assay | Inhibitory activity against nitric oxide production in lipopolysaccharide-activated mouse macrophage RAW264.7 cells, IC50=15.9μM. | 14552759 | ||
HL60 | Function assay | In vitro inhibitory concentration against proliferation of HL60 cells, IC50=5μM. | 12877593 | ||
CHO | Function assay | Blockade of human Glut3 expressed in CHO cells assessed as inhibition of [14C]dehydroascorbic acid uptake by scintillation spectrometry | 11277764 | ||
CHO | Function assay | Blockade of human Glut3 expressed in CHO cells assessed as inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake by scintillation spectrometry | 11277764 | ||
CHO | Function assay | Blockade of rat Glut1 expressed in CHO cells assessed as inhibition of [14C]dehydroascorbic acid uptake by scintillation spectrometry | 11277764 | ||
CHO | Function assay | Blockade of rat Glut1 expressed in CHO cells assessed as inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake by scintillation spectrometry | 11277764 | ||
HL60 | Function assay | Inhibition of [14C]dehydroascorbic acid uptake in human HL60 cells by scintillation spectrometry in presence of sodium-free buffer | 11277764 | ||
U937 | Function assay | Inhibition of [14C]dehydroascorbic acid uptake in human U937 cells by scintillation spectrometry in presence of sodium-free buffer | 11277764 | ||
HL60 | Function assay | Inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake in human HL60 cells by scintillation spectrometry in presence of sodium-free buffer | 11277764 | ||
U937 | Function assay | Inhibition of 2-[1,2-3H(N)]deoxy-D-glucose uptake in human U937 cells by scintillation spectrometry in presence of sodium-free buffer | 11277764 | ||
U937 | Function assay | Inhibition of [14C]dehydroascorbic acid uptake in human U937 cells by Michaelis-Menten plot, Ki=35μM. | 11277764 | ||
human K562 cell line | Proliferation assay | Antiproliferative activity against human K562 cell line expressing Bcr-Abl, IC50=28 μM | 16686543 | ||
human HL60 cell line | Proliferation assay | Antiproliferative activity against human HL60 cell line, IC50=5 μM | 16686543 | ||
MDA-MB-231 | Function assay | Reversal of induction of FOXO3a activity in human MDA-MB-231 cells transfected with FOXO3a-specific small interfering RNA | 17513867 | ||
MDA-MB-231 | Function assay | Induction of FOXO3a activity in human MDA-MB-231 cells | 17513867 | ||
MC3T3-E1 | Function assay | Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays in presence of short interfering ER alpha-RNA | 17513867 | ||
MC3T3-E1 | Function assay | Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays in presence of ICI-182780 | 17513867 | ||
MC3T3-E1 | Function assay | Increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays | 17513867 | ||
MC3T3-E1 | Function assay | Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells transfected with dominant-negative mutant Src expression vector by electrophoretic mobility shift assays | 17513867 | ||
MC3T3-E1 | Function assay | Reversal of increase in DNA-binding activity of ERalpha in nuclear extracts of mouse MC3T3-E1 cells by electrophoretic mobility shift assays in presence of PP2 | 17513867 | ||
MDA-MB-231 | Function assay | Reversal of inhibition in anchorage-independent colony formation of human MDA-MB-231 cells transfected with FOXO3a-specific small interfering RNA by soft agar colony forming assay | 17513867 | ||
MDA-MB-231 | Function assay | Inhibition of IGF-induced FOXO3a phosphorylation at Thr32 residue in human MDA-MB-231 cells by Western blot | 17513867 | ||
MDA-MB-231 | Function assay | Inhibition of IGF-induced Akt phosphorylation in human MDA-MB-231 cells by Western blot | 17513867 | ||
MDA-MB-231 | Function assay | Reversal of induction of Akt inactivation in human MDA-MB-231 cells transfected with constitutively activated Akt mutant | 17513867 | ||
MDA-MB-231 | Function assay | Reversal of induction of FOXO3a nuclear accumulation in human MDA-MB-231 cells transfected with constitutively activated Akt mutant | 17513867 | ||
MDA-MB-231 | Function assay | Reversal of induction of FOXO3a activity in human MDA-MB-231 cells transfected with constitutively activated Akt mutant | 17513867 | ||
MDA-MB-231 | Function assay | Enhancement of Akt inactivation in human MDA-MB-231 cells transfected with dominant negative Akt mutant | 17513867 | ||
MDA-MB-231 | Function assay | Enhancement of FOXO3a nuclear accumulation in human MDA-MB-231 cells transfected with dominant negative Akt mutant | 17513867 | ||
MDA-MB-231 | Function assay | Enhancement of FOXO3a activity in human MDA-MB-231 cells transfected with dominant negative Akt mutant | 17513867 | ||
RAW264.7 | Function assay | Inhibition of phagocytosis of FITC-conjugated Escherichia coli K12 in mouse RAW264.7 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry | 17938187 | ||
RAW264.7 | Function assay | Inhibition of phagocytosis of FITC-conjugated Staphylococcus aureus 209P in mouse RAW264.7 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry | 17938187 | ||
THP1 | Function assay | Inhibition of phagocytosis of FITC-conjugated Escherichia coli K12 in human THP1 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry | 17938187 | ||
THP1 | Function assay | Inhibition of phagocytosis of FITC-conjugated Staphylococcus aureus 209P in human THP1 cells assessed as reduction in ratio of number of bacterial cells to phagocytes using trypan blue staining by flow cytometry | 17938187 | ||
Hepa 1c1c7 | Function assay | Inhibition of quinone reductase 1 in mouse Hepa 1c1c7 cells assessed as drug level required to double enzyme activity by MTT assay, CD=21μM. | 20527891 | ||
HEK293 | Function assay | Inhibition of TNFalpha-activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay, IC50=0.98μM. | 22115839 | ||
Hepa-1c1c7 | Function assay | Induction of QR1 activity in mouse Hepa-1c1c7 cells using MTT as substrate by spectrophotometry, CD=21μM. | 22115839 | ||
HEK293 | Function assay | Inhibition of TNF-alpha activated NF-kappaB expressed in HEK293 cells by luciferase reporter gene assay, IC50=0.98μM. | 22386564 | ||
Hepa-1c1c7 | Function assay | Induction of QR1 in mouse Hepa-1c1c7 cells assessed as concentration required to double QR1 induction by MTT assay, CD=21μM. | 22386564 | ||
HEK293 | Function assay | Inhibition of TNFalpha-induced NF-kappaB activity expressed in HEK293 cells by luciferase reporter gene assay, IC50=0.98μM. | 23142320 | ||
HeLa | Function assay | Inhibition of smad3/4 signaling pathway in human HeLa cells assessed as measured as lowest concentration required 50 to 60 % inhibition of TGF-beta induced luciferase treated 30 mins before induction, MED=33μM. | 23547843 | ||
HeLa | Function assay | Inhibition of Hedgehog signaling pathway in human HeLa cells assessed as measured as lowest concentration required 50 to 60 % inhibition of PMA induced luciferase treated 30 mins before induction, MED=40μM. | 23547843 | ||
HeLa | Function assay | Inhibition of Hedgehog signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction, IC50=40μM. | 23547843 | ||
HeLa | Function assay | Inhibition of Notch signaling pathway in human HeLa cells assessed as measured as lowest concentration required 50 to 60 % inhibition of PMA induced luciferase treated 30 mins before induction, MED=40μM. | 23547843 | ||
HeLa | Function assay | Inhibition of Notch signaling pathway in human HeLa cells assessed as inhibition of PMA induced luciferase treated 30 mins before induction, IC50=40μM. | 23547843 | ||
HL60 | Cytotoxicity assay | Cytotoxicity against human HL60 cells, ED50=22μM. | 23582778 | ||
COLO205 | Antiproliferative assay | Antiproliferative activity against human COLO205 cells by MTT assay, IC50=23.5μM. | 25455486 | ||
MGC803 | Antiproliferative assay | Antiproliferative activity against human MGC803 cells by MTT assay, IC50=42μM. | 25455486 | ||
MDA468 | Antiproliferative assay | Antiproliferative activity against human MDA468 cells by MTT assay, IC50=45.2μM. | 25455486 | ||
HEK293 | Function assay | Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of AITC-induced increase of intracellular calcium level, IC50=0.75μM. | 26750258 | ||
HEK293 | Function assay | Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in absence of AITC, IC50=1.4μM. | 26750258 | ||
HEK293 | Function assay | Agonist activity at rat TRPA1 expressed in HEK293 cells assessed as induction of intracellular calcium level in presence of AITC, IC50=2.74μM. | 26750258 | ||
HEK293 | Function assay | Antagonist activity at rat TRPA1 expressed in HEK293 cells assessed as inhibition of allyl isothiocyanate-induced increase of intracellular calcium level, IC50=19.9μM. | 26750258 | ||
HEK293 | Function assay | Inhibition of human TRPA1 expressed in HEK293 cells assessed as decrease in AITC-induced current response by whole cell patch clamp method, IC50=0.75μM. | 28576617 | ||
A549 | Growth inhibition assay | Growth inhibition of human A549 cells, IC50=30μM. | 28814374 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
HBZY-1 | Function assay | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Nrf2 nuclear translocation by measuring increase in ratio of nuclear to cytosolic Nrf2 level by Western blot analysis | 31301564 | ||
HBZY-1 | Function assay | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in NQO-1 protein expression by Western blot analysis | 31301564 | ||
HBZY-1 | Function assay | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in HO-1 protein expression by Western blot analysis | 31301564 | ||
HBZY-1 | Function assay | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLM protein expression by Western blot analysis | 31301564 | ||
HBZY-1 | Function assay | Binding affinity to Keap1 in rat HBZY-1 cells assessed as induction of Keap1/Nrf2 signaling by measuring increase in GCLC protein expression by Western blot analysis | 31301564 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Resveratrol具有廣泛靶點,包括環(huán)氧酶(如COX, IC50=1.1 μM)、脂肪氧合酶(LOC, IC50=2.7 μM)、sirtuins和其他蛋白質(zhì)。它是一種天然的植物抗毒素,具有抗癌,抗炎,降血糖和其他有益心血管的作用。Resveratrol可誘導線粒體自噬、細胞自噬和自噬依賴性的凋亡。 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Resveratro 抑制環(huán)氧合酶和脂氧化酶,PKCs和p56lck, ERK1,JNK1,p38,IKK β,Src,STAT3,核苷酸還原酶,DNA聚合酶α和 δ,PKD,PKC α,醌還原酶2,以及芳香化酶的活性,IC50值為0.035-60 μM。Resveratrol也是腺苷酸環(huán)化酶和AMPK的活化劑,IC50值分別為0.8 μM和50 μM。Resveratrol作為抑制劑或活化劑,能夠減少細胞炎癥相關(guān)的表現(xiàn),抑制癌癥細胞的生長并誘導細胞凋亡,逆轉(zhuǎn)內(nèi)皮素-1受激的細胞應(yīng)答,抑制佛波醇酯誘導的COX-2表達,抑制細胞中DNA合成,抵抗甲萘醌誘導的細胞死亡,并且改善細胞線粒體功能和葡萄糖/脂質(zhì)代謝。[1]Resveratrol也是抗衰老酶的活化劑。Resveratrol降低作用于乙酰化底物和NAD+的SIRT1的Michaelis常數(shù),通過促進SIRT1依賴性的p53脫乙酰作用增加細胞存活。在酵母中,Resveratrol通過刺激Sir2模擬熱量限制,增加DNA穩(wěn)定性并延長壽命。[2] Resveratrol通過其抗氧化活性,能夠有效保護離體的大鼠心臟免受心臟缺血/再灌注損傷,改善發(fā)展壓和主動脈血流的恢復,降低丙二醛的濃度并減少梗死面積。[3] | |||
---|---|---|---|---|
細胞實驗 | 細胞系 | 人類乳腺癌細胞MCF-7 | ||
濃度 | 30-300 μM | |||
孵育時間 | 2天 | |||
方法 | 細胞接種于平底96孔微量滴定板(4000細胞/ 6.4毫米直徑的孔)。在12-24小時后,細胞用DMSO(0.1–0.3%)處理或者增加Resveratrol的劑量。治療48小時后,細胞用10μL 的MTT試劑在37℃下處理4小時,然后用100 μL增溶溶液在37 ℃下處理過夜。甲臜產(chǎn)生的數(shù)量利用分光光度微量滴定板讀數(shù)器在570nm波長下測量。 |
|||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot | Nanog / Oct-4 / Sox-2 p-EGFR / EGFR / p-HER2 / HER2 / p-ERK / ERK / PTEN | 21304978 | ||
Growth inhibition assay | Cell viability | 23272133 |
體內(nèi)研究(In Vivo) | ||
體內(nèi)研究活性 | Resveratrol改善高熱量飲食小鼠的健康和生存。Resveratrol (22.4 毫克/千克/天)使高熱量飲食中年小鼠的生理機能轉(zhuǎn)變?yōu)榕c標準飲食小鼠相符,并且顯著增加他們的存活率。Resveratrol產(chǎn)生與延長壽命相關(guān)的改變,包括增加胰島素敏感性,降低胰島素樣生長因子-1(IGF-I)的水平,增加AMP活化的蛋白激酶(AMPK) 過氧化物酶體增殖物激活的受體-γ共激活因子1α(PGC-1α)的活性,增加線粒體數(shù)量,并改善運動機能。在153顯著改變的通路中,Resveratrol能夠抵抗144的高熱量飲食作用。[3] 在各種嚙齒動物癌癥模型中,Resveratrol被證明能夠抑制腫瘤的發(fā)生和生長。Resveratrol在低至200微克/千克劑量下已經(jīng)在結(jié)腸癌變的大鼠模型中表現(xiàn)出了功效。在40毫克/千克的較高劑量下,Resveratrol使患有皮下成神經(jīng)細胞瘤的小鼠的存活率從0%增加到70%。Resveratrol在48微克/千克劑量下每天給藥,抑制小鼠角膜微囊袋法中血管形成。[3] Resveratrol對心臟疾病表現(xiàn)出有益作用。Resveratrol阻斷高脂飲食誘發(fā)的血小板聚集的增加。Resveratrol增加內(nèi)皮細胞和誘導型一氧化氮合酶的表達。在易卒型自發(fā)性高血壓大鼠體內(nèi),Resveratrol顯著降低氧化應(yīng)激的標志物,如血清中的糖化白蛋白和尿液中的8-羥基鳥嘌呤核苷。Resveratrol加入到飲用水中15天(1 毫克/千克)足以改善離體心臟的功能和冠狀動脈血流量的恢復。[3] Resveratrol在體內(nèi)顯示抗炎活性。Resveratrol顯著降低急慢性化學誘發(fā)的水腫,脂多糖誘發(fā)的氣道炎癥和骨關(guān)節(jié)炎,并且有助于防止同種異體移植排斥。在大鼠體內(nèi),Resveratrol靜脈注射給藥降低局部缺血/再灌注誘發(fā)的炎癥,減少次黃嘌呤/黃嘌呤氧化酶(HX/ XO)或血小板活化因子產(chǎn)生的氧化劑,但不影響白三烯B4。[3] Resveratrol顯示出對中風和腦損傷的有益作用。Resveratrol在100納克/千克和1 微克/千克的極低劑量下靜脈注射給藥,顯著減少大鼠大腦中動脈閉塞后缺血體積和腦組織含水量。[5] | |
---|---|---|
動物實驗 | Animal Models | 人類卵巢異種移植物PA-1 |
Dosages | 100毫克/千克 | |
Administration | 每天腹腔注射連續(xù)四周 |
NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
---|---|---|---|---|---|
NCT05684848 | Recruiting | Wheezing|Recurrent Respiratory Tract Infections |
Noos S.r.l. |
November 1 2022 | Not Applicable |
NCT03743636 | Completed | Peripheral Artery Disease |
Northwestern University|American Heart Association |
October 1 2018 | Phase 3 |
分子量 | 228.24 | 分子式 | C14H12O3 |
CAS號 | 501-36-0 | SDF | Download Resveratrol SDF |
Smiles | C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O | ||
儲存條件(自收到貨起) | |||
體外溶解度 |
DMSO : 46 mg/mL ( (201.54 mM) ;DMSO吸濕會降低化合物溶解度,請使用新開封DMSO) Water : Insoluble Ethanol : Insoluble |
摩爾濃度計算器 |
體內(nèi)溶解度 現(xiàn)配現(xiàn)用,請按從左到右的順序依次添加,澄清后再加入下一溶劑 |
動物體內(nèi)配方計算器 |
動物體內(nèi)配方計算器(澄清溶液)
第一步:請輸入基本實驗信息(考慮到實驗過程中的損耗,建議多配一只動物的藥量)
第二步:請輸入動物體內(nèi)配方組成(配方適用于不溶于水的藥物;不同批次藥物配方比例不同,請聯(lián)系Selleck為您提供正確的澄清溶液配方)
計算結(jié)果:
工作液濃度: mg/ml;
DMSO母液配制方法: mg 藥物溶于μL DMSO溶液(母液濃度mg/mL,注:如該濃度超過該批次藥物DMSO溶解度,請先聯(lián)系Selleck);
體內(nèi)配方配制方法:取μL DMSO母液,加入μL PEG300,混勻澄清后加入μL Tween 80,混勻澄清后加入μL ddH2O,混勻澄清。
體內(nèi)配方配制方法:取μL DMSO母液,加入μL Corn oil,混勻澄清。
注意:1. 首先保證母液是澄清的;
2.一定要按照順序依次將溶劑加入,進行下一步操作之前必須保證上一步操作得到的是澄清的溶液,可采用渦旋、超聲或水浴加熱等物理方法助溶。
在訂購、運輸、儲存和使用我們的產(chǎn)品的任何階段,您遇到的任何問題,均可以通過撥打我們的熱線電話400-668-6834,或者技術(shù)支持郵箱tech@selleck.cn,直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題,請給我們留言。
* 必填項